A detailed history of Enterprise Financial Services Corp transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Enterprise Financial Services Corp holds 194 shares of REGN stock, worth $141,678. This represents 0.12% of its overall portfolio holdings.

Number of Shares
194
Previous 194 -0.0%
Holding current value
$141,678
Previous $203,000 -0.0%
% of portfolio
0.12%
Previous 0.13%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$883.2 - $1071.19 $171,340 - $207,810
194 New
194 $203,000
Q3 2021

Nov 15, 2021

SELL
$574.03 - $680.96 $70,605 - $83,758
-123 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$472.8 - $558.54 $51,062 - $60,322
108 Added 720.0%
123 $69,000
Q1 2021

May 13, 2021

SELL
$446.73 - $548.2 $14,295 - $17,542
-32 Reduced 68.09%
15 $7,000
Q4 2020

Feb 12, 2021

BUY
$478.3 - $607.98 $10,044 - $12,767
21 Added 80.77%
47 $22,000
Q3 2020

Nov 13, 2020

BUY
$544.75 - $658.21 $1,089 - $1,316
2 Added 8.33%
26 $15,000
Q2 2020

Aug 04, 2020

SELL
$493.32 - $643.92 $40,452 - $52,801
-82 Reduced 77.36%
24 $15,000
Q1 2020

May 15, 2020

BUY
$336.18 - $494.43 $34,962 - $51,420
104 Added 5200.0%
106 $52,000
Q4 2019

Jan 28, 2020

BUY
$274.13 - $376.51 $548 - $753
2 New
2 $1,000
Q3 2019

Oct 31, 2019

SELL
$273.46 - $318.39 $3,828 - $4,457
-14 Closed
0 $0
Q2 2019

Jul 30, 2019

BUY
$299.6 - $414.82 $3,894 - $5,392
13 Added 1300.0%
14 $4,000
Q3 2018

Oct 26, 2018

BUY
$351.14 - $408.51 $351 - $408
1 New
1 $0
Q1 2018

Apr 27, 2018

SELL
$315.82 - $393.78 $1,894 - $2,362
-6 Closed
0 $0
Q4 2017

Jan 26, 2018

SELL
$358.63 - $469.95 $4,662 - $6,109
-13 Reduced 68.42%
6 $2,000
Q3 2017

Oct 27, 2017

BUY
$431.38 - $504.0 $8,196 - $9,576
19
19 $8,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $78.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Enterprise Financial Services Corp Portfolio

Follow Enterprise Financial Services Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

News

Stay updated on Enterprise Financial Services Corp with notifications on news.